Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study



Summary

This phase II study explored the efficacy of adding sintilimab (an anti-PD-1 immunotherapy) to standard neoadjuvant chemoradiotherapy (nCRT) for patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) rectal cancer expressing PD-L1 (TPS ≥ 1% or CPS ≥ 1). The open-label trial aimed to improve treatment outcomes for this traditionally difficult-to-treat subgroup. Preliminary findings suggest potential benefits in pathological complete response (pCR) rates and overall response, warranting further investigation in larger, randomized controlled trials to confirm these findings and assess long-term outcomes. The study represents a promising avenue for improving outcomes in pMMR/MSS rectal cancer.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!